06 May 2022
It has taken French rare disease specialist Orphalan 11 years to earn its first approval in the U.S. But that’s nothing compared to how long people with Wilson’s disease have waited for a new medicine for their debilitating condition.
Monday, when the FDA signed off (PDF) on Cuvrior (trientine tetrahydrochloride), it became the first treatment approved for the condition in 52 years.
Wilson’s is an inherited disorder that prevents the liver from filtering copper out of the system, causing a toxic buildup and organ damage. It’s estimated that 10,000 people in the U.S. have Wilson’s disease, with only about half of them identified as it often is misdiagnosed as a more common type of liver disease.
Before the first treatment for Wilson’s, patients rarely lived beyond age 30. But that changed with the introduction Cuprimine (penicillamine) in 1970.
Cuvrior shares the same mechanism as penicillamine as both attach to copper to form a compound that can be excreted. But dosing of both drugs is onerous; patients take 8 to 12 pills several times per day on an empty stomach.
“It’s inherently an unstable compound,” said Orphalan CEO Naseem Amin said in an interview. “We developed a novel salt which is truly room-temperature stable. You can take the pack with you wherever you are. You can put it in your pocket, in your bag. Just pop it out of the blister pack, take it with a drink and you’re good to go.”
Patients can take Cuvrior after they’ve been “de-coppered” with chelating agents which block copper absorption from the gastrointestinal tract. After the chelating, a patient goes on Cuvrior and zinc for lifelong maintenance.
Orphalan expects to launch Cuvrior in the U.S. early next year and do its own marketing of the drug.
This is not the first regulatory endorsement for the drug. In 2017, it won approval in Europe as a second-line treatment for Wilson’s disease in the 30% to 40% of Wilson’s patients who develop an intolerance to penicillamine.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024